BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAH4. A total of 52 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,067,000 | +8.6% | 1,100,000 | +10.0% | 0.14% | +5.1% |
| Q2 2023 | $982,268 | -4.3% | 1,000,000 | 0.0% | 0.14% | -4.2% |
| Q1 2023 | $1,025,979 | -3.3% | 1,000,000 | 0.0% | 0.14% | -1.4% |
| Q4 2022 | $1,061,300 | +7.1% | 1,000,000 | 0.0% | 0.14% | -2.0% |
| Q3 2022 | $991,000 | +0.1% | 1,000,000 | 0.0% | 0.15% | +2.8% |
| Q2 2022 | $990,000 | -1.0% | 1,000,000 | 0.0% | 0.14% | +16.1% |
| Q1 2022 | $1,000,000 | -4.4% | 1,000,000 | 0.0% | 0.12% | +2.5% |
| Q4 2021 | $1,046,000 | +2.2% | 1,000,000 | 0.0% | 0.12% | -7.6% |
| Q3 2021 | $1,023,000 | -1.3% | 1,000,000 | 0.0% | 0.13% | +0.8% |
| Q2 2021 | $1,036,000 | +2.4% | 1,000,000 | 0.0% | 0.13% | +0.8% |
| Q1 2021 | $1,012,000 | +88.5% | 1,000,000 | +100.0% | 0.13% | +92.5% |
| Q4 2020 | $537,000 | – | 500,000 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SHENKMAN CAPITAL MANAGEMENT INC | 30,138,000 | $29,510,000 | 3.72% |
| PFM Health Sciences, LP | 45,910,000 | $46,002,000 | 1.72% |
| Cheyne Capital Management (UK) LLP | 2,320,000 | $2,330,000 | 1.47% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 41,077,000 | $41,277,000 | 0.66% |
| SSI INVESTMENT MANAGEMENT LLC | 9,071,000 | $9,068,000 | 0.50% |
| PALISADE CAPITAL MANAGEMENT, LP | 14,548,000 | $14,612,000 | 0.34% |
| RWC Asset Management LLP | 7,500,000 | $7,552,000 | 0.21% |
| KBC Group NV | 400,000 | $40,316,000 | 0.15% |
| PROSPECTOR PARTNERS LLC | 1,000,000 | $1,000,000 | 0.12% |
| MACKAY SHIELDS LLC | 11,822,000 | $11,816,000 | 0.10% |